Compare Adecoagro SA (AGRO) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Cytokinetics Inc — how do they compare? Adecoagro SA trades at $9.67 (market cap $1.36B), while Cytokinetics Inc trades at $77.39 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 7.8× Adecoagro SA's market cap, and Adecoagro SA pays a 3.15% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| AGRO | CYTK | |
|---|---|---|
Market Cap | $1.36B | $10.63B |
Sector | Technology | Technology |
52-Week High | $15.25 | $87.26 |
52-Week Low | $7.13 | $34.31 |
Enterprise Value | $3.39B | $10.74B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.45, up 0.96% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported negative net income of -$8.35M for 2025 despite $1.43B revenue, though 2026 projections show potential profitability improvement. Recent acquisition of Caarapó Mill expands operational footprint while analyst consensus leans neutral with 50% hold ratings.
Outlook remains cautious with elevated P/E ratio of 536.67 offset by attractive P/B of 0.79. Key risks include commodity volatility and integration challenges from recent acquisitions. The stock presents value opportunity if 2026 profitability targets are achieved, but requires careful monitoring of earnings trajectory.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
